Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings

Overview

Journal AIDS Res Treat

Publisher Wiley

Specialty Infectious Diseases

Date 2011 Apr 15

PMID 21490779

Citations 19

Authors

Kevin Peterson

Sabelle Jallow

Sarah L Rowland-Jones

Thushan I de Silva

Affiliations

Soon will be listed here.

Abstract

HIV-2 contributes approximately a third to the prevalence of HIV in West Africa and is present in significant amounts in several low-income countries outside of West Africa with historical ties to Portugal. It complicates HIV diagnosis, requiring more expensive and technically demanding testing algorithms. Natural polymorphisms and patterns in the development of resistance to antiretrovirals are reviewed, along with their implications for antiretroviral therapy. Nonnucleoside reverse transcriptase inhibitors, crucial in standard first-line regimens for HIV-1 in many low-income settings, have no effect on HIV-2. Nucleoside analogues alone are not sufficiently potent enough to achieve durable virologic control. Some protease inhibitors, in particular those without ritonavir boosting, are not sufficiently effective against HIV-2. Following review of the available evidence and taking the structure and challenges of antiretroviral care in West Africa into consideration, the authors make recommendations and highlight the needs of special populations.

Citing Articles

Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds.

Moranguinho I, Taveira N, Bartolo I Int J Mol Sci. 2023; 24(6).

PMID: 36982978 PMC: 10053740. DOI: 10.3390/ijms24065905.

HIV-2: still off the radar for India's 90-90-90 targets.

Khopkar-Kale P, Kulkarni S Indian J Med Res. 2021; 154(1):24-26.

PMID: 34782527 PMC: 8715681. DOI: 10.4103/ijmr.IJMR_828_19.

Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa.

Tchounga B, Charpentier C, Coffie P, Dabis F, Descamps D, Eholie S PLoS One. 2020; 15(8):e0236642.

PMID: 32756581 PMC: 7406077. DOI: 10.1371/journal.pone.0236642.

The implementation and evaluation of HIV symptom management guidelines: A preliminary study in China.

Zhu Z, Hu Y, Li H, Bao M, Zhang L, Zha L Int J Nurs Sci. 2019; 5(4):315-321.

PMID: 31406842 PMC: 6626266. DOI: 10.1016/j.ijnss.2018.08.005.

T cell functionality in HIV-1, HIV-2 and dually infected individuals: correlates of disease progression and immune restoration.

Salwe S, Padwal V, Nagar V, Patil P, Patel V Clin Exp Immunol. 2019; 198(2):233-250.

PMID: 31216050 PMC: 6797902. DOI: 10.1111/cei.13342.

References

Barreto J, Liljestrand J, Palha de Sousa C, Bergstrom S, Bottiger B, Biberfeld G . HIV-1 and HIV-2 antibodies in pregnant women in the City of Maputo, Mozambique. A comparative study between 1982/1983 and 1990. Scand J Infect Dis. 1993; 25(6):685-8. DOI: 10.3109/00365549309008563. View

Rockstroh J, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L . European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008; 9(2):82-8. DOI: 10.1111/j.1468-1293.2007.00535.x. View

Lhomme R, Nijland H, Gras L, Aarnoutse R, van Crevel R, Boeree M . Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS. 2009; 23(7):863-5. DOI: 10.1097/QAD.0b013e328329148e. View

Alabi A, Jaffar S, Ariyoshi K, Blanchard T, Schim van der Loeff M, Awasana A . Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients. AIDS. 2003; 17(10):1513-20. DOI: 10.1097/00002030-200307040-00012. View

Lennox J, DeJesus E, Berger D, Lazzarin A, Pollard R, Madruga J . Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010; 55(1):39-48. PMC: 6065510. DOI: 10.1097/QAI.0b013e3181da1287. View

Ntemgwa M, Toni T, Brenner B, Camacho R, Wainberg M . Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother. 2009; 53(9):3611-9. PMC: 2737883. DOI: 10.1128/AAC.00154-09. View

Patick A, Mo H, Markowitz M, Appelt K, Wu B, Musick L . Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother. 1996; 40(2):292-7. PMC: 163104. DOI: 10.1128/AAC.40.2.292. View

Ota M, ODonovan D, Alabi A, Milligan P, Yamuah L, NGom P . Maternal HIV-1 and HIV-2 infection and child survival in The Gambia. AIDS. 2000; 14(4):435-9. DOI: 10.1097/00002030-200003100-00018. View

Damond F, Brun-Vezinet F, Matheron S, Peytavin G, Campa P, Pueyo S . Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J Clin Microbiol. 2005; 43(1):484-7. PMC: 540186. DOI: 10.1128/JCM.43.1.484-487.2005. View

10.

Moyle G . The K65R mutation: selection, frequency, and possible consequences. AIDS Read. 2004; 14(11):595-7, 601-3. View

11.

Rouet F, Chaix M, Inwoley A, Msellati P, Viho I, Combe P . HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d'Ivoire: the ANRS 1236 study. J Med Virol. 2004; 74(1):34-40. DOI: 10.1002/jmv.20143. View

12.

Wakefield J, Jablonski S, Morrow C . In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J Virol. 1992; 66(11):6806-12. PMC: 240183. DOI: 10.1128/JVI.66.11.6806-6812.1992. View

13.

Isaka Y, Miki S, Kawauchi S, Suyama A, Sugimoto H, Adachi A . A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors. Arch Virol. 2001; 146(4):743-55. DOI: 10.1007/s007050170143. View

14.

Colson P, Henry M, Tivoli N, Gallais H, Gastaut J, Moreau J . Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France. J Med Virol. 2005; 75(3):381-90. DOI: 10.1002/jmv.20296. View

15.

Kirk G, Lesi O, Mendy M, Akano A, Sam O, Goedert J . The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology. 2004; 39(1):211-9. DOI: 10.1002/hep.20027. View

16.

POULSEN A, Aaby P, Gottschau A, Kvinesdal B, Dias F, Molbak K . HIV-2 infection in Bissau, West Africa, 1987-1989: incidence, prevalences, and routes of transmission. J Acquir Immune Defic Syndr (1988). 1993; 6(8):941-8. View

17.

Tong L, Pav S, Pargellis C, DO F, Lamarre D, Anderson P . Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures. Proc Natl Acad Sci U S A. 1993; 90(18):8387-91. PMC: 47361. DOI: 10.1073/pnas.90.18.8387. View

18.

Ghosn J, De Montgolfier I, Cornelie C, Dominguez S, Perot C, Peytavin G . Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy. Antimicrob Agents Chemother. 2008; 52(4):1542-4. PMC: 2292558. DOI: 10.1128/AAC.01301-07. View

19.

Steigbigel R, Cooper D, Teppler H, Eron J, Gatell J, Kumar P . Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010; 50(4):605-12. PMC: 6076431. DOI: 10.1086/650002. View

20.

Shi Y, Brandin E, Vincic E, Jansson M, Blaxhult A, Gyllensten K . Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J Gen Virol. 2005; 86(Pt 12):3385-3396. DOI: 10.1099/vir.0.81259-0. View